Press Releases

Date Title
Toggle Summary Novel, Oral Drug TTP488 Shows Promise for Disease Modification in Alzheimer’s Patients
High Point, North Carolina (October 29, 2012) A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer’s disease. TTP488 is a small-molecule drug that is the first to